Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

EXCLUSIVE: Retired David Mather was dealt a shocking blow when told his tiredness was stage-IV lung cancer - now a new UK ...

Patients with extensive-stage small cell lung cancer (ES-SCLC ... to treat patients with resectable non–small cell lung cancer (NSCLC) as a neoadjuvant treatment with chemotherapy and continued ...

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's ...

Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...